Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium
Late-breaking presentation highlights durable clinical activity, including 57% overall response rate at recommended Phase 2 dose in biomarker-positive patients Time on REM-422 treatment reached up to two years and remains ongoing, supporting potential for long term dosing…
